S&P 500   4,547.99 (-0.05%)
DOW   35,393.28 (+0.17%)
QQQ   388.93 (-0.06%)
AAPL   189.80 (+0.01%)
MSFT   381.05 (+0.64%)
META   336.04 (+0.40%)
GOOGL   136.55 (+0.10%)
AMZN   146.86 (-0.59%)
TSLA   245.43 (+3.96%)
NVDA   475.94 (-1.34%)
NIO   7.19 (+0.00%)
BABA   76.30 (-1.59%)
AMD   121.43 (-0.99%)
T   16.12 (-0.56%)
F   10.34 (+0.00%)
MU   75.10 (-3.11%)
CGC   0.53 (-2.41%)
GE   118.98 (-0.83%)
DIS   93.38 (-1.88%)
AMC   6.67 (-1.91%)
PFE   29.71 (-1.43%)
PYPL   58.37 (+3.51%)
XOM   104.31 (+0.34%)
S&P 500   4,547.99 (-0.05%)
DOW   35,393.28 (+0.17%)
QQQ   388.93 (-0.06%)
AAPL   189.80 (+0.01%)
MSFT   381.05 (+0.64%)
META   336.04 (+0.40%)
GOOGL   136.55 (+0.10%)
AMZN   146.86 (-0.59%)
TSLA   245.43 (+3.96%)
NVDA   475.94 (-1.34%)
NIO   7.19 (+0.00%)
BABA   76.30 (-1.59%)
AMD   121.43 (-0.99%)
T   16.12 (-0.56%)
F   10.34 (+0.00%)
MU   75.10 (-3.11%)
CGC   0.53 (-2.41%)
GE   118.98 (-0.83%)
DIS   93.38 (-1.88%)
AMC   6.67 (-1.91%)
PFE   29.71 (-1.43%)
PYPL   58.37 (+3.51%)
XOM   104.31 (+0.34%)
S&P 500   4,547.99 (-0.05%)
DOW   35,393.28 (+0.17%)
QQQ   388.93 (-0.06%)
AAPL   189.80 (+0.01%)
MSFT   381.05 (+0.64%)
META   336.04 (+0.40%)
GOOGL   136.55 (+0.10%)
AMZN   146.86 (-0.59%)
TSLA   245.43 (+3.96%)
NVDA   475.94 (-1.34%)
NIO   7.19 (+0.00%)
BABA   76.30 (-1.59%)
AMD   121.43 (-0.99%)
T   16.12 (-0.56%)
F   10.34 (+0.00%)
MU   75.10 (-3.11%)
CGC   0.53 (-2.41%)
GE   118.98 (-0.83%)
DIS   93.38 (-1.88%)
AMC   6.67 (-1.91%)
PFE   29.71 (-1.43%)
PYPL   58.37 (+3.51%)
XOM   104.31 (+0.34%)
S&P 500   4,547.99 (-0.05%)
DOW   35,393.28 (+0.17%)
QQQ   388.93 (-0.06%)
AAPL   189.80 (+0.01%)
MSFT   381.05 (+0.64%)
META   336.04 (+0.40%)
GOOGL   136.55 (+0.10%)
AMZN   146.86 (-0.59%)
TSLA   245.43 (+3.96%)
NVDA   475.94 (-1.34%)
NIO   7.19 (+0.00%)
BABA   76.30 (-1.59%)
AMD   121.43 (-0.99%)
T   16.12 (-0.56%)
F   10.34 (+0.00%)
MU   75.10 (-3.11%)
CGC   0.53 (-2.41%)
GE   118.98 (-0.83%)
DIS   93.38 (-1.88%)
AMC   6.67 (-1.91%)
PFE   29.71 (-1.43%)
PYPL   58.37 (+3.51%)
XOM   104.31 (+0.34%)

West Pharmaceutical Services (WST) Stock Forecast & Price Target

$353.59
-0.31 (-0.09%)
(As of 02:08 PM ET)
Compare
Today's Range
$351.80
$356.79
50-Day Range
$318.29
$392.61
52-Week Range
$221.82
$415.73
Volume
130,808 shs
Average Volume
439,224 shs
Market Capitalization
$26.16 billion
P/E Ratio
47.72
Dividend Yield
0.23%
Price Target
$355.00

West Pharmaceutical Services Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$355.00
0.40% Upside
High Forecast$440.00
Average Forecast$355.00
Low Forecast$250.00
TypeCurrent Forecast
11/28/22 to 11/28/23
1 Month Ago
10/29/22 to 10/29/23
3 Months Ago
8/30/22 to 8/30/23
1 Year Ago
11/28/21 to 11/28/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$355.00$355.00$361.00$300.00
Predicted Upside0.40% Upside10.96% Upside9.91% Upside35.61% Upside
Get West Pharmaceutical Services Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for WST and its competitors with MarketBeat's FREE daily newsletter.


WST Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

West Pharmaceutical Services Stock vs. The Competition

TypeWest Pharmaceutical ServicesMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside-0.18% Downside962.18% Upside2,838.46% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/27/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$420.00 ➝ $390.00+20.06%
8/30/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$415.00 ➝ $440.00+6.67%
6/16/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$390.00 ➝ $405.00+12.56%
2/22/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$250.00 ➝ $290.00-5.29%
11/30/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$250.00+11.86%
(Data available from 11/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












WST Price Target - Frequently Asked Questions

What is West Pharmaceutical Services's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for West Pharmaceutical Services stock is Moderate Buy based on the current 2 hold ratings and 3 buy ratings for WST. The average twelve-month price prediction for West Pharmaceutical Services is $355.00 with a high price target of $440.00 and a low price target of $250.00. Learn more on WST's analyst rating history.

Do Wall Street analysts like West Pharmaceutical Services more than its competitors?

Analysts like West Pharmaceutical Services less than other Medical companies. The consensus rating score for West Pharmaceutical Services is 2.60 while the average consensus rating score for medical companies is 2.67. Learn more on how WST compares to other companies.

Does West Pharmaceutical Services's stock price have much upside?

According to analysts, West Pharmaceutical Services's stock has a predicted upside of 10.96% based on their 12-month stock forecasts.

What analysts cover West Pharmaceutical Services?

West Pharmaceutical Services has been rated by KeyCorp, and Stephens in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:WST) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -